{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T09:29:46Z","timestamp":1793179786807,"version":"4.5.0"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,3,22]],"date-time":"2025-03-22T00:00:00Z","timestamp":1742601600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,3,22]],"date-time":"2025-03-22T00:00:00Z","timestamp":1742601600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"crossref","award":["R01 DA047855"],"award-info":[{"award-number":["R01 DA047855"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"crossref","award":["UG\/UH3DA048353"],"award-info":[{"award-number":["UG\/UH3DA048353"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"crossref","award":["R21 DA055908"],"award-info":[{"award-number":["R21 DA055908"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Drug Metab Pharmacokinet"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1007\/s13318-025-00939-2","type":"journal-article","created":{"date-parts":[[2025,3,23]],"date-time":"2025-03-23T03:02:27Z","timestamp":1742698947000},"page":"205-218","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["In Vitro and In Vivo Pharmacokinetic Characterization of 7-Hydroxymitragynine, an Active Metabolite of Mitragynine, in Sprague-Dawley Rats"],"prefix":"10.1007","volume":"50","author":[{"given":"Yi-Hua","family":"Chiang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siva Rama Raju","family":"Kanumuri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle A.","family":"Kuntz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandria S.","family":"Senetra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erin C.","family":"Berthold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shyam H.","family":"Kamble","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sushobhan","family":"Mukhopadhyay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aidan J.","family":"Hampson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher R.","family":"McCurdy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0553-4039","authenticated-orcid":false,"given":"Abhisheak","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,22]]},"reference":[{"issue":"04","key":"939_CR1","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1055\/a-0770-3683","volume":"85","author":"BA Avery","year":"2019","unstructured":"Avery BA, Boddu SP, Sharma A, Furr EB, Leon F, Cutler SJ, et al. Comparative pharmacokinetics of mitragynine after oral administration of Mitragyna speciosa (Kratom) leaf extracts in rats. Planta Med. 2019;85(04):340\u20136. https:\/\/doi.org\/10.1055\/a-0770-3683.","journal-title":"Planta Med"},{"issue":"2","key":"939_CR2","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1016\/j.neubiorev.2012.11.012","volume":"37","author":"Z Hassan","year":"2013","unstructured":"Hassan Z, Muzaimi M, Navaratnam V, Yusoff NH, Suhaimi FW, Vadivelu R, et al. From Kratom to mitragynine and its derivatives: physiological and behavioural effects related to use, abuse, and addiction. Neurosci Biobehav Rev. 2013;37(2):138\u201351. https:\/\/doi.org\/10.1016\/j.neubiorev.2012.11.012.","journal-title":"Neurosci Biobehav Rev"},{"issue":"5","key":"939_CR3","doi-asserted-by":"publisher","first-page":"874","DOI":"10.1111\/adb.12639","volume":"24","author":"SE Hemby","year":"2019","unstructured":"Hemby SE, McIntosh S, Leon F, Cutler SJ, McCurdy CR. Abuse liability and therapeutic potential of the Mitragyna speciosa (kratom) alkaloids mitragynine and 7-hydroxymitragynine. Addict Biol. 2019;24(5):874\u201385. https:\/\/doi.org\/10.1111\/adb.12639.","journal-title":"Addict Biol"},{"issue":"12","key":"939_CR4","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.2174\/1389450118666170925154025","volume":"19","author":"K-Y Chin","year":"2018","unstructured":"Chin K-Y, Mark-Lee WF. A review on the antinociceptive effects of Mitragyna speciosa and its derivatives on animal model. Curr Drug Targets. 2018;19(12):1359\u201365. https:\/\/doi.org\/10.2174\/1389450118666170925154025.","journal-title":"Curr Drug Targets"},{"issue":"9","key":"939_CR5","doi-asserted-by":"publisher","first-page":"11427","DOI":"10.3390\/ijms130911427","volume":"13","author":"AR Shamima","year":"2012","unstructured":"Shamima AR, Fakurazi S, Hidayat MT, Hairuszah I, Moklas MAM, Arulselvan P. Antinociceptive action of isolated mitragynine from Mitragyna speciosa through activation of opioid receptor system. Int J Mol Sci. 2012;13(9):11427\u201342. https:\/\/doi.org\/10.3390\/ijms130911427.","journal-title":"Int J Mol Sci"},{"key":"939_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/j.neulet.2022.136500","volume":"773","author":"N Harun","year":"2022","unstructured":"Harun N, Kamaruzaman NA, Sofian ZM, Hassan Z. Mini review: potential therapeutic values of mitragynine as an opioid substitution therapy. Neurosci Lett. 2022;773: 136500. https:\/\/doi.org\/10.1016\/j.neulet.2022.136500.","journal-title":"Neurosci Lett"},{"issue":"1","key":"939_CR7","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1021\/acs.jmedchem.9b01465","volume":"63","author":"S Obeng","year":"2019","unstructured":"Obeng S, Kamble SH, Reeves ME, Restrepo LF, Patel A, Behnke M, et al. Investigation of the adrenergic and opioid binding affinities, metabolic stability, plasma protein binding properties, and functional effects of selected indole-based kratom alkaloids. J Med Chem. 2019;63(1):433\u20139. https:\/\/doi.org\/10.1021\/acs.jmedchem.9b01465.","journal-title":"J Med Chem"},{"issue":"18","key":"939_CR8","doi-asserted-by":"publisher","first-page":"8381","DOI":"10.1021\/acs.jmedchem.6b00748","volume":"59","author":"A V\u00e1radi","year":"2016","unstructured":"V\u00e1radi A, Marrone GF, Palmer TC, Narayan A, Szab\u00f3 MR, Le Rouzic V, et al. Mitragynine\/corynantheidine pseudoindoxyls as opioid analgesics with mu agonism and delta antagonism, which do not recruit \u03b2-arrestin-2. J Med Chem. 2016;59(18):8381\u201397. https:\/\/doi.org\/10.1021\/acs.jmedchem.6b00748.","journal-title":"J Med Chem"},{"issue":"3","key":"939_CR9","doi-asserted-by":"publisher","first-page":"620","DOI":"10.3390\/pharmaceutics14030620","volume":"14","author":"RS Tanna","year":"2022","unstructured":"Tanna RS, Nguyen JT, Hadi DL, Manwill PK, Flores-Bocanegra L, Layton ME, et al. Clinical pharmacokinetic assessment of kratom (Mitragyna speciosa), a botanical product with opioid-like effects, in healthy adult participants. Pharmaceutics. 2022;14(3):620. https:\/\/doi.org\/10.3390\/pharmaceutics14030620.","journal-title":"Pharmaceutics"},{"issue":"6","key":"939_CR10","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1021\/acsptsci.0c00075","volume":"3","author":"SH Kamble","year":"2020","unstructured":"Kamble SH, Le\u00f3n F, King TI, Berthold EC, Lopera-Londo\u00f1o C, Siva Rama Raju K, et al. Metabolism of a kratom alkaloid metabolite in human plasma increases its opioid potency and efficacy. ACS Pharmacol Transl Sci. 2020;3(6):1063\u20138. https:\/\/doi.org\/10.1021\/acsptsci.0c00075.","journal-title":"ACS Pharmacol Transl Sci."},{"issue":"17","key":"939_CR11","doi-asserted-by":"publisher","first-page":"2143","DOI":"10.1016\/j.lfs.2003.09.054","volume":"74","author":"K Matsumoto","year":"2004","unstructured":"Matsumoto K, Horie S, Ishikawa H, Takayama H, Aimi N, Ponglux D, et al. Antinociceptive effect of 7-hydroxymitragynine in mice: discovery of an orally active opioid analgesic from the Thai medicinal herb Mitragyna speciosa. Life Sci. 2004;74(17):2143\u201355. https:\/\/doi.org\/10.1016\/j.lfs.2003.09.054.","journal-title":"Life Sci"},{"issue":"1","key":"939_CR12","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/j.lfs.2004.10.086","volume":"78","author":"K Matsumoto","year":"2005","unstructured":"Matsumoto K, Horie S, Takayama H, Ishikawa H, Aimi N, Ponglux D, et al. Antinociception, tolerance and withdrawal symptoms induced by 7-hydroxymitragynine, an alkaloid from the Thai medicinal herb Mitragyna speciosa. Life Sci. 2005;78(1):2\u20137. https:\/\/doi.org\/10.1016\/j.lfs.2004.10.086.","journal-title":"Life Sci"},{"issue":"2","key":"939_CR13","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1124\/dmd.121.000640","volume":"50","author":"EC Berthold","year":"2022","unstructured":"Berthold EC, Kamble SH, Raju KS, Kuntz MA, Senetra AS, Mottinelli M, et al. The lack of contribution of 7-hydroxymitragynine to the antinociceptive effects of mitragynine in mice: a pharmacokinetic and pharmacodynamic study. Drug Metab Dispos. 2022;50(2):158\u201367. https:\/\/doi.org\/10.1124\/dmd.121.000640.","journal-title":"Drug Metab Dispos"},{"issue":"6","key":"939_CR14","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1021\/acscentsci.9b00141","volume":"5","author":"AC Kruegel","year":"2019","unstructured":"Kruegel AC, Uprety R, Grinnell SG, Langreck C, Pekarskaya EA, Le Rouzic V, et al. 7-Hydroxymitragynine is an active metabolite of mitragynine and a key mediator of its analgesic effects. ACS Cent Sci. 2019;5(6):992\u20131001. https:\/\/doi.org\/10.1021\/acscentsci.9b00141.","journal-title":"ACS Cent Sci"},{"issue":"12","key":"939_CR15","doi-asserted-by":"publisher","first-page":"1726","DOI":"10.1002\/bmc.2986","volume":"27","author":"PK Vuppala","year":"2013","unstructured":"Vuppala PK, Jamalapuram S, Furr EB, McCurdy CR, Avery BA. Development and validation of a UPLC-MS\/MS method for the determination of 7-hydroxymitragynine, a \u03bc-opioid agonist, in rat plasma and its application to a pharmacokinetic study. Biomed Chromatogr. 2013;27(12):1726\u201332. https:\/\/doi.org\/10.1002\/bmc.2986.","journal-title":"Biomed Chromatogr"},{"key":"939_CR16","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1007\/s13318-021-00684-2","volume":"46","author":"EA Maxwell","year":"2021","unstructured":"Maxwell EA, King TI, Kamble SH, Raju KSR, Berthold EC, Le\u00f3n F, et al. Oral pharmacokinetics in beagle dogs of the mitragynine metabolite, 7-hydroxymitragynine. Eur J Drug Metab Pharmacokinet. 2021;46:459\u201363. https:\/\/doi.org\/10.1007\/s13318-021-00684-2.","journal-title":"Eur J Drug Metab Pharmacokinet"},{"issue":"3","key":"939_CR17","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1006\/taap.2002.9440","volume":"182","author":"TA Baillie","year":"2002","unstructured":"Baillie TA, Cayen MN, Fouda H, Gerson RJ, Green JD, Grossman SJ, et al. Drug metabolites in safety testing. Toxicol Appl Pharmacol. 2002;182(3):188\u201396. https:\/\/doi.org\/10.1006\/taap.2002.9440.","journal-title":"Toxicol Appl Pharmacol"},{"issue":"5","key":"939_CR18","doi-asserted-by":"publisher","first-page":"984","DOI":"10.3390\/molecules29050984","volume":"29","author":"MA Huestis","year":"2024","unstructured":"Huestis MA, Brett MA, Bothmer J, Atallah R. Human mitragynine and 7-hydroxymitragynine pharmacokinetics after single and multiple daily doses of oral encapsulated dried kratom leaf powder. Molecules. 2024;29(5):984. https:\/\/doi.org\/10.3390\/molecules29050984.","journal-title":"Molecules"},{"issue":"3","key":"939_CR19","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1021\/acsptsci.3c00335","volume":"7","author":"P Mongar","year":"2024","unstructured":"Mongar P, Jaisi A, Inkviya T, Wungsintaweekul J, Wiwattanawongsa K. Effects of itraconazole on pharmacokinetics of mitragynine and 7-hydroxymitragynine in healthy volunteers. ACS Pharmacol Transl Sci. 2024;7(3):823\u201333. https:\/\/doi.org\/10.1021\/acsptsci.3c00335.","journal-title":"ACS Pharmacol Transl Sci."},{"issue":"9","key":"939_CR20","doi-asserted-by":"publisher","first-page":"1949","DOI":"10.1021\/jm010576e","volume":"45","author":"H Takayama","year":"2002","unstructured":"Takayama H, Ishikawa H, Kurihara M, Kitajima M, Aimi N, Ponglux D, et al. Studies on the synthesis and opioid agonistic activities of mitragynine-related indole alkaloids: discovery of opioid agonists structurally different from other opioid ligands. J Med Chem. 2002;45(9):1949\u201356. https:\/\/doi.org\/10.1021\/jm010576e.","journal-title":"J Med Chem"},{"issue":"17","key":"939_CR21","doi-asserted-by":"publisher","first-page":"1278","DOI":"10.1055\/a-1212-5475","volume":"86","author":"EA Maxwell","year":"2020","unstructured":"Maxwell EA, King TI, Kamble SH, Raju KSR, Berthold EC, Le\u00f3n F, et al. Pharmacokinetics and safety of mitragynine in beagle dogs. Planta Med. 2020;86(17):1278\u201385. https:\/\/doi.org\/10.1055\/a-1212-5475.","journal-title":"Planta Med"},{"issue":"8","key":"939_CR22","doi-asserted-by":"publisher","first-page":"2452","DOI":"10.1021\/acsptsci.4c00277","volume":"7","author":"Y-H Chiang","year":"2024","unstructured":"Chiang Y-H, Berthold EC, Kuntz MA, Kanumuri SRR, Senetra AS, Mukhopadhyay S, et al. Multiple-dose pharmacokinetics and safety of mitragynine, the major alkaloid of kratom. Rats ACS Pharmacol Transl Sci. 2024;7(8):2452\u201364. https:\/\/doi.org\/10.1021\/acsptsci.4c00277.","journal-title":"Rats. ACS Pharmacol Transl Sci."},{"key":"939_CR23","doi-asserted-by":"publisher","DOI":"10.1002\/dta.3703","author":"YH Chiang","year":"2024","unstructured":"Chiang YH, Chear NJY, Berthold EC, Kuntz MA, Kanumuri SRR, Senetra AS, et al. Preclinical pharmacokinetic studies of villocarine A, an active Uncaria alkaloid. Drug Test Anal. 2024. https:\/\/doi.org\/10.1002\/dta.3703.","journal-title":"Drug Test Anal"},{"issue":"6","key":"939_CR24","doi-asserted-by":"publisher","first-page":"2498","DOI":"10.1002\/jps.22452","volume":"100","author":"MJ Zamek-Gliszczynski","year":"2011","unstructured":"Zamek-Gliszczynski MJ, Ruterbories KJ, Ajamie RT, Wickremsinhe ER, Pothuri L, Rao MV, et al. Validation of 96-well equilibrium dialysis with non-radiolabeled drug for definitive measurement of protein binding and application to clinical development of highly-bound drugs. J Pharm Sci. 2011;100(6):2498\u2013507. https:\/\/doi.org\/10.1002\/jps.22452.","journal-title":"J Pharm Sci"},{"key":"939_CR25","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-62703-742-6","volume-title":"Optimization in drug discovery. Vitro methods","year":"2014","unstructured":"Caldwell GW, Yan Z, editors. Optimization in drug discovery. Vitro methods. 2nd ed. New York: Humana Press; 2014. https:\/\/doi.org\/10.1007\/978-1-62703-742-6.","edition":"2"},{"key":"939_CR26","doi-asserted-by":"publisher","DOI":"10.2147\/dddt.s83055","author":"Z Huang","year":"2015","unstructured":"Huang Z, Li H, Zhang Q, Tan X, Lu F, Liu H, et al. Characterization of preclinical in vitro and in vivo pharmacokinetics properties for KBP-7018, a new tyrosine kinase inhibitor candidate for treatment of idiopathic pulmonary fibrosis. Drug Des Devel Ther. 2015. https:\/\/doi.org\/10.2147\/dddt.s83055.","journal-title":"Drug Des Devel Ther."},{"issue":"2","key":"939_CR27","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1002\/rcm.1777","volume":"19","author":"S Yu","year":"2005","unstructured":"Yu S, Li S, Yang H, Lee F, Wu JT, Qian MG. A novel liquid chromatography\/tandem mass spectrometry based depletion method for measuring red blood cell partitioning of pharmaceutical compounds in drug discovery. Rapid Commun Mass Spectrom. 2005;19(2):250\u20134. https:\/\/doi.org\/10.1002\/rcm.1777.","journal-title":"Rapid Commun Mass Spectrom"},{"issue":"5","key":"939_CR28","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1208\/s12248-022-00736-8","volume":"24","author":"SH Kamble","year":"2022","unstructured":"Kamble SH, Berthold EC, Kanumuri SRR, King TI, Kuntz MA, Le\u00f3n F, et al. Metabolism of speciociliatine, an overlooked kratom alkaloid for its potential pharmacological effects. AAPS J. 2022;24(5):86. https:\/\/doi.org\/10.1208\/s12248-022-00736-8.","journal-title":"AAPS J"},{"issue":"10","key":"939_CR29","doi-asserted-by":"publisher","first-page":"1316","DOI":"10.1124\/dmd.29.10.1316","volume":"29","author":"Y Naritomi","year":"2001","unstructured":"Naritomi Y, Terashita S, Kimura S, Suzuki A, Kagayama A, Sugiyama Y. Prediction of human hepatic clearance from in vivo animal experiments and in vitro metabolic studies with liver microsomes from animals and humans. Drug Metab Dispos. 2001;29(10):1316\u201324. https:\/\/doi.org\/10.1124\/dmd.29.10.1316","journal-title":"Drug Metab Dispos"},{"key":"939_CR30","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.2012.35","volume-title":"Drug metabolism and pharmacokinetics quick guide","author":"SC Khojasteh","year":"2011","unstructured":"Khojasteh SC, Wong H, Hop CE. Drug metabolism and pharmacokinetics quick guide. New York: Springer Science & Business Media; 2011. https:\/\/doi.org\/10.1038\/clpt.2012.35."},{"issue":"9","key":"939_CR31","doi-asserted-by":"publisher","first-page":"637","DOI":"10.3109\/00498254.2010.500407","volume":"40","author":"A-K Sohlenius-Sternbeck","year":"2010","unstructured":"Sohlenius-Sternbeck A-K, Afzelius L, Prusis P, Neelissen J, Hoogstraate J, Johansson J, et al. Evaluation of the human prediction of clearance from hepatocyte and microsome intrinsic clearance for 52 drug compounds. Xenobiotica. 2010;40(9):637\u201349. https:\/\/doi.org\/10.3109\/00498254.2010.500407.","journal-title":"Xenobiotica"},{"key":"939_CR32","unstructured":"United States Food and Drug Administration. bioanalytical method validation: guidance for industry. US Department of Health and Human Services, Center for Drug Evaluation and Research; 2018. Accessed 11 Nov 2024."},{"issue":"1","key":"939_CR33","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/s0378-5173(01)00698-6","volume":"222","author":"G Krishna","year":"2001","unstructured":"Krishna G, Chen K-J, Lin C-C, Nomeir AA. Permeability of lipophilic compounds in drug discovery using in-vitro human absorption model, Caco-2. Int J Pharm. 2001;222(1):77\u201389. https:\/\/doi.org\/10.1016\/s0378-5173(01)00698-6.","journal-title":"Int J Pharm"},{"issue":"9","key":"939_CR34","doi-asserted-by":"publisher","first-page":"1490","DOI":"10.1023\/a:1011930411574","volume":"15","author":"M Yazdanian","year":"1998","unstructured":"Yazdanian M, Glynn SL, Wright JL, Hawi A. Correlating partitioning and Caco-2 cell permeability of structurally diverse small molecular weight compounds. Pharm Res. 1998;15(9):1490. https:\/\/doi.org\/10.1023\/a:1011930411574.","journal-title":"Pharm Res"},{"issue":"6","key":"939_CR35","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1002\/jps.1031","volume":"90","author":"YH Zhao","year":"2001","unstructured":"Zhao YH, Le J, Abraham MH, Hersey A, Eddershaw PJ, Luscombe CN, et al. Evaluation of human intestinal absorption data and subsequent derivation of a quantitative structure\u2013activity relationship (QSAR) with the Abraham descriptors. J Pharm Sci. 2001;90(6):749\u201384. https:\/\/doi.org\/10.1002\/jps.1031.","journal-title":"J Pharm Sci"},{"issue":"4","key":"939_CR36","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1007\/s11418-018-1222-x","volume":"72","author":"T Matsumoto","year":"2018","unstructured":"Matsumoto T, Kaifuchi N, Mizuhara Y, Warabi E, Watanabe J. Use of a Caco-2 permeability assay to evaluate the effects of several Kampo medicines on the drug transporter P-glycoprotein. J Nat Med. 2018;72(4):897\u2013904. https:\/\/doi.org\/10.1007\/s11418-018-1222-x.","journal-title":"J Nat Med"},{"key":"939_CR37","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.bbrc.2023.02.021","volume":"651","author":"D Dimitrijevic","year":"2023","unstructured":"Dimitrijevic D, Fabian E, Funk-Weyer D, Landsiedel R. Rapid equilibrium dialysis, ultrafiltration or ultracentrifugation? Evaluation of methods to quantify the unbound fraction of substances in plasma. Biochem Biophys Res Commun. 2023;651:114\u201320. https:\/\/doi.org\/10.1016\/j.bbrc.2023.02.021.","journal-title":"Biochem Biophys Res Commun"},{"issue":"2","key":"939_CR38","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1002\/jps.2600760204","volume":"76","author":"KK Chan","year":"1987","unstructured":"Chan KK, Vyas KH, Brandt KD. In vitro protein binding of diclofenac sodium in plasma and synovial fluid. J Pharm Sci. 1987;76(2):105\u20138. https:\/\/doi.org\/10.1002\/jps.2600760204.","journal-title":"J Pharm Sci"},{"key":"939_CR39","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.ajp.2019.05.016","volume":"43","author":"K Ya","year":"2019","unstructured":"Ya K, Tangamornsuksan W, Scholfield CN, Methaneethorn J, Lohitnavy M. Pharmacokinetics of mitragynine, a major analgesic alkaloid in kratom (Mitragyna speciosa): a systematic review. Asian J Psychiatr. 2019;43:73\u201382. https:\/\/doi.org\/10.1016\/j.ajp.2019.05.016.","journal-title":"Asian J Psychiatr"},{"issue":"3","key":"939_CR40","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1016\/S0031-6997(24)01329-2","volume":"49","author":"PH Hinderling","year":"1997","unstructured":"Hinderling PH. Red blood cells: a neglected compartment in pharmacokinetics and pharmacodynamics. Pharmacol Rev. 1997;49(3):279\u201395.\u00a0https:\/\/doi.org\/10.1016\/S0031-6997(24)01329-2","journal-title":"Pharmacol Rev"},{"issue":"7","key":"939_CR41","doi-asserted-by":"publisher","first-page":"3067","DOI":"10.1128\/aac.01433-10","volume":"55","author":"MA Zeitlinger","year":"2011","unstructured":"Zeitlinger MA, Derendorf H, Mouton JW, Cars O, Craig WA, Andes D, et al. Protein binding: do we ever learn? Antimicrob Agents Chemother. 2011;55(7):3067\u201374. https:\/\/doi.org\/10.1128\/aac.01433-10.","journal-title":"Antimicrob Agents Chemother"},{"key":"939_CR42","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1007\/bf03189651","volume":"9","author":"F Keller","year":"1984","unstructured":"Keller F, Maiga M, Neumayer H-H, Lode H, Distler A. Pharmacokinetic effects of altered plasma protein binding of drugs in renal disease. Eur J Drug Metab Pharmacokinet. 1984;9:275\u201382. https:\/\/doi.org\/10.1007\/bf03189651.","journal-title":"Eur J Drug Metab Pharmacokinet"},{"key":"939_CR43","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.1208\/s12248-016-9962-6","volume":"18","author":"UA Argikar","year":"2016","unstructured":"Argikar UA, Potter PM, Hutzler JM, Marathe PH. Challenges and opportunities with non-CYP enzymes aldehyde oxidase, carboxylesterase, and UDP-glucuronosyltransferase: focus on reaction phenotyping and prediction of human clearance. AAPS J. 2016;18:1391\u2013405. https:\/\/doi.org\/10.1208\/s12248-016-9962-6.","journal-title":"AAPS J"},{"key":"939_CR44","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1016\/j.ejmech.2012.06.043","volume":"57","author":"L Di","year":"2012","unstructured":"Di L, Keefer C, Scott DO, Strelevitz TJ, Chang G, Bi Y-A, et al. Mechanistic insights from comparing intrinsic clearance values between human liver microsomes and hepatocytes to guide drug design. Eur J Med Chem. 2012;57:441\u20138. https:\/\/doi.org\/10.1016\/j.ejmech.2012.06.043.","journal-title":"Eur J Med Chem"},{"issue":"11","key":"939_CR45","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1080\/00498254.2018.1552819","volume":"49","author":"SH Kamble","year":"2019","unstructured":"Kamble SH, Sharma A, King TI, Le\u00f3n F, McCurdy CR, Avery BA. Metabolite profiling and identification of enzymes responsible for the metabolism of mitragynine, the major alkaloid of Mitragyna speciosa (kratom). Xenobiotica. 2019;49(11):1279\u201388. https:\/\/doi.org\/10.1080\/00498254.2018.1552819.","journal-title":"Xenobiotica"},{"key":"939_CR46","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1007\/978-1-0716-1542-3_5","volume-title":"Cytochrome P450 methods in pharmacology and toxicology","author":"J Wang","year":"2021","unstructured":"Wang J. Cytochrome P450 enzyme kinetics: Km and Vmax determinations using metabolite formation and substrate depletion methods. Cytochrome P450: in vitro methods and protocol. In: Yan Z, Caldwell GW, editors. Cytochrome P450 methods in pharmacology and toxicology. New York: Humana; 2021. p. 79\u201390. https:\/\/doi.org\/10.1007\/978-1-0716-1542-3_5."},{"issue":"5","key":"939_CR47","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1111\/adb.12661","volume":"24","author":"SR Yusof","year":"2019","unstructured":"Yusof SR, Mohd Uzid M, Teh EH, Hanapi NA, Mohideen M, Mohamad Arshad AS, et al. Rate and extent of mitragynine and 7-hydroxymitragynine blood\u2013brain barrier transport and their intra-brain distribution: the missing link in pharmacodynamic studies. Addict Biol. 2019;24(5):935\u201345. https:\/\/doi.org\/10.1111\/adb.12661.","journal-title":"Addict Biol"},{"issue":"07","key":"939_CR48","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1055\/s-0034-1368444","volume":"80","author":"VK Manda","year":"2014","unstructured":"Manda VK, Avula B, Ali Z, Khan IA, Walker LA, Khan SI. Evaluation of in vitro absorption, distribution, metabolism, and excretion (ADME) properties of mitragynine, 7-hydroxymitragynine, and mitraphylline. Planta Med. 2014;80(07):568\u201376. https:\/\/doi.org\/10.1055\/s-0034-1368444.","journal-title":"Planta Med"},{"issue":"3","key":"939_CR49","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1124\/jpet.122.001525","volume":"385","author":"SH Kamble","year":"2023","unstructured":"Kamble SH, Obeng S, Le\u00f3n F, Restrepo LF, King TI, Berthold EC, et al. Pharmacokinetic and pharmacodynamic consequences of cytochrome P450 3A inhibition on mitragynine metabolism in rats. J Pharmacol Exp Ther. 2023;385(3):180\u201392. https:\/\/doi.org\/10.1124\/jpet.122.001525.","journal-title":"J Pharmacol Exp Ther"},{"issue":"1","key":"939_CR50","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/s0306-3623(98)00265-1","volume":"33","author":"LT Yamamoto","year":"1999","unstructured":"Yamamoto LT, Horie S, Takayama H, Aimi N, Sakai S-I, Yano S, et al. Opioid receptor agonistic characteristics of mitragynine pseundoxyl in comparison with mitragynine derived from Thai medicinal plant Mitragyna speciosa. Gen Pharmacol. 1999;33(1):73\u201381. https:\/\/doi.org\/10.1016\/s0306-3623(98)00265-1.","journal-title":"Gen Pharmacol"},{"key":"939_CR51","doi-asserted-by":"publisher","DOI":"10.1096\/fasebj.2021.35.S1.05475","author":"M Crowley","year":"2021","unstructured":"Crowley M, Obeng S, Patel A, Gamez-Jimenez L, Restrepo L, Ho N, et al. Assessment of contribution of 7-hydroxymitragynine and mitragynine pseundoxyl to the MU-opioid activity of mitragynine. FASEB J. 2021. https:\/\/doi.org\/10.1096\/fasebj.2021.35.S1.05475.","journal-title":"FASEB J"},{"issue":"1","key":"939_CR52","doi-asserted-by":"publisher","first-page":"3590","DOI":"10.1038\/s41467-022-31342-z","volume":"13","author":"MTH Tuhin","year":"2022","unstructured":"Tuhin MTH, Liang D, Liu F, Aldawod H, Amin TU, Ho JS, et al. Peripherally restricted transthyretin-based delivery system for probes and therapeutics avoiding opioid-related side effects. Nat Commun. 2022;13(1):3590. https:\/\/doi.org\/10.1038\/s41467-022-31342-z.","journal-title":"Nat Commun"},{"issue":"1","key":"939_CR53","doi-asserted-by":"publisher","first-page":"18782","DOI":"10.1038\/s41598-019-55325-1","volume":"9","author":"R Watanabe","year":"2019","unstructured":"Watanabe R, Ohashi R, Esaki T, Kawashima H, Natsume-Kitatani Y, Nagao C, et al. Development of an in silico prediction system of human renal excretion and clearance from chemical structure information incorporating fraction unbound in plasma as a descriptor. Sci Rep. 2019;9(1):18782. https:\/\/doi.org\/10.1038\/s41598-019-55325-1.","journal-title":"Sci Rep"},{"issue":"1","key":"939_CR54","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1006\/bbrc.1997.7904","volume":"242","author":"GR Robertson","year":"1998","unstructured":"Robertson GR, Farrell GC, Liddle C. Sexually dimorphic expression of rat CYP3A9 and CYP3A18 genes is regulated by growth hormone. Biochem Biophys Res Commun. 1998;242(1):57\u201360. https:\/\/doi.org\/10.1006\/bbrc.1997.7904.","journal-title":"Biochem Biophys Res Commun"},{"issue":"2","key":"939_CR55","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1248\/bpb.28.311","volume":"28","author":"T Aiba","year":"2005","unstructured":"Aiba T, Yoshinaga M, Ishida K, Takehara Y, Hashimoto Y. Intestinal expression and metabolic activity of the CYP3A subfamily in female rats. Biol Pharm Bull. 2005;28(2):311\u20135. https:\/\/doi.org\/10.1248\/bpb.28.311.","journal-title":"Biol Pharm Bull"},{"key":"939_CR56","doi-asserted-by":"publisher","DOI":"10.4172\/2157-7609.1000119","author":"L Yang","year":"2012","unstructured":"Yang L, Li Y, Hong H, Chang C-W, Guo L-W, Lyn-Cook B, et al. Sex differences in the expression of drug-metabolizing and transporter genes in human liver. J Drug Metab Toxicol. 2012. https:\/\/doi.org\/10.4172\/2157-7609.1000119.","journal-title":"J Drug Metab Toxicol."},{"issue":"3","key":"939_CR57","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0236770","volume":"16","author":"MS Thomsen","year":"2021","unstructured":"Thomsen MS, Humle N, Hede E, Moos T, Burkhart A, Thomsen LB. The blood-brain barrier studied in vitro across species. PLoS ONE. 2021;16(3): e0236770. https:\/\/doi.org\/10.1371\/journal.pone.0236770.","journal-title":"PLoS ONE"}],"container-title":["European Journal of Drug Metabolism and Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13318-025-00939-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13318-025-00939-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13318-025-00939-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,15]],"date-time":"2025-05-15T14:09:34Z","timestamp":1747318174000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13318-025-00939-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,22]]},"references-count":57,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["939"],"URL":"https:\/\/doi.org\/10.1007\/s13318-025-00939-2","relation":{},"ISSN":["0378-7966","2107-0180"],"issn-type":[{"value":"0378-7966","type":"print"},{"value":"2107-0180","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,22]]},"assertion":[{"value":"2 March 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 March 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This research was funded by grants R01 DA047855, UG\/UH3DA048353, and R21 DA055908 from the National Institute on Drug Abuse.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Considered upon request.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Material"}},{"value":"The views and opinions expressed in this article are those of the authors only and do not necessarily represent the views, official policy, or position of the US Department of Health and Human Services or any of its affiliated institutions or agencies. Dr. Hampson was substantially involved in UG\/H3DA048353, consistent with his role as Scientific Officer. He had no substantial involvement in the other cited grants. The authors declare no conflict of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"All the animal studies were performed after approval from the University of Florida Institutional Animal Care and Use Committee (202110396).","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}}]}}